News | March 08, 2022
Industry upbeat on biopharma sector
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Subscribe To Our Newsletter & Stay Updated
